Congress seeks explanation for stealth anti-FoB maneuver by FDA: http://www.pharmalive.com/senators-to-fda-has-biosimliar-naming-policy-changed I think this FoB-naming issue is no big deal, but other investors think it is, so it’s worth following for that reason.